Brighton Collaboration

Last updated
The Brighton Collaboration
Formation2000 (2000)
Type NPO
PurposeSafest, effective vaccines based on rigorous science
To enhance the science of vaccine research by providing standardized, validated, and objective methods for continuous monitoring of safety profiles and by assessing benefit-risk ratios. These methods are, in turn, recognized and recommended for use by international regulatory and public health agencies. [1]
Headquarters Basel, Switzerland
Region served
Worldwide
Official language
English
LeaderJan Bonhoeffer, president
Parent organization
Task Force for Global Health
Affiliations Coalition for Epidemic Preparedness Innovations
Website brightoncollaboration.us

The Brighton Collaboration (BC) is a non-profit global vaccine safety research network based in Basel, Switzerland. It is named after the city in England where the idea was first formulated. [2]

Contents

History

The Brighton Collaboration was launched in 2000, although the idea of the collaboration started one year earlier, following a presentation by Bob Chen at an international scientific vaccine conference in Brighton. In his talk, he stressed the need to improve vaccine safety monitoring by developing internationally accepted standards. [3]

Organization

The Brighton Collaboration is a program of the Task Force for Global Health, a 501(c)(3) non-profit organization. It is primarily funded by the Coalition for Epidemic Preparedness Innovations (CEPI), and has received funding from a variety of scientific and public health organizations since its inception. [4]

Non-funding partners of the Collaboration include the Council for International Organizations of Medical Sciences, European Medicines Agency, Food and Drug Administration and the World Health Organization. [4]

Related Research Articles

<span class="mw-page-title-main">Vaccine</span> Pathogen-derived preparation that provides acquired immunity to an infectious disease

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

<span class="mw-page-title-main">Medical research</span> Wide array of research

Medical research, also known as experimental medicine, encompasses a wide array of research, extending from "basic research", – involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials. Within this spectrum is applied research, or translational research, conducted to expand knowledge in the field of medicine.

<span class="mw-page-title-main">Canadian Institutes of Health Research</span>

The Canadian Institutes of Health Research is a federal agency responsible for funding health and medical research in Canada. Comprising 13 institutes, it is the successor to the Medical Research Council of Canada.

<span class="mw-page-title-main">International AIDS Vaccine Initiative</span> Not-for-profit, public-private partnership

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS. IAVI researches and develops vaccine candidates, conducts policy analyses, serves as an advocate for the HIV prevention field and engages communities in the trial process and AIDS vaccine education. The organization takes a comprehensive approach to HIV and AIDS that supports existing HIV prevention and treatment programs while emphasizing the need for new AIDS prevention tools. It also works to ensure that future vaccines will be accessible to all who need them.

The American College of Preventive Medicine (ACPM) is an American non-profit organization focused on practice, research, publication, and teaching of evidence-based preventive medicine. It publishes the American Journal of Preventive Medicine, which is their official journal.

The Vaccine Safety Datalink Project (VSD) was established in 1990 by the United States Centers for Disease Control and Prevention (CDC) to study the adverse effects of vaccines.

A Patient Safety Organization (PSO) is a group, institution, or association that improves medical care by reducing medical errors. Common functions of patient safety organizations are data collection, analysis, reporting, education, funding, and advocacy. A PSO differs from a Federally designed Patient Safety Organization (PSO), which provides health care providers in the U.S. privilege and confidentiality protections for efforts to improve patient safety and the quality of patient care delivery

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">HIV Vaccine Trials Network</span>

The HIV Vaccine Trials Network (HVTN) is a non-profit organization which connects physicians and scientists with activists and community educators for the purpose of conducting clinical trials seeking a safe and effective HIV vaccine. Collaboratively, researchers and laypeople review potential vaccines for safety, immune response, and efficacy. The HVTN is a network for testing vaccines, and while its members may also work in vaccine development for other entities, the mission of the HVTN does not include vaccine design.

<span class="mw-page-title-main">German Agency for Quality in Medicine</span>

The German Agency for Quality in Medicine (AEZQ) - in German "Ärztliches Zentrum für Qualität in der Medizin (ÄZQ)", established in 1995 and located in Berlin, co-ordinates healthcare quality programmes with special focus on evidence-based medicine, medical guidelines, patient empowerment, patient safety programs, and quality management.

<span class="mw-page-title-main">MediaSmarts</span> Canadian non-profit organization and registered charity

MediaSmarts is a Canadian non-profit organization and registered charity based in Ottawa, Ontario, that focuses on digital and media literacy programs and resources. In particular, the organization promotes critical thinking via educational resources and analyzes the content of various types of mass media.

The International Human Epigenome Consortium (IHEC) is a scientific organization, founded in 2010, that helps to coordinate global efforts in the field of Epigenomics. The initial goal was to generate at least 1,000 reference (baseline) human epigenomes from different types of normal and disease-related human cell types.

This page is a timeline of global health, including major conferences, interventions, cures, and crises.

Extensive investigation into vaccines and autism spectrum disorder has shown that there is no relationship between the two, causal or otherwise, and that the vaccine ingredients do not cause autism. Vaccinologist Peter Hotez researched the growth of the false claim and concluded that its spread originated with Andrew Wakefield's fraudulent 1998 paper, with no prior paper supporting a link.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">Solidarity trial</span> Accelerated multinational clinical trial program to identify therapies against COVID-19

The Solidarity trial for treatments is a multinational Phase III-IV clinical trial organized by the World Health Organization (WHO) and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. The trial was announced 18 March 2020, and as of 6 August 2021, 12,000 patients in 30 countries had been recruited to participate in the trial.

Science diplomacy is the collaborative efforts by local and global entities to solve global issues using science and technology as a base. In science diplomacy, collaboration takes place to advance science but science can also be used to facilitate diplomatic relations. This allows even conflicting nations to come together through science to find solutions to global issues. Global organizations, researchers, public health officials, countries, government officials, and clinicians have previously worked together to create effective measures of infection control and subsequent treatment. They continue to do so through sharing of resources, research data, ideas, and by putting into effect laws and regulations that can further advance scientific research. Without the collaborative efforts of such entities, the world would not have the vaccines and treatments we now possess for diseases that were once considered deadly such as tuberculosis, tetanus, polio, influenza, etc. Historically, science diplomacy has proved successful in diseases such as SARS, Ebola, Zika and continues to be relevant during the COVID-19 pandemic today.

<span class="mw-page-title-main">Vaccine Safety Net</span> Network of medical information websites

Vaccine Safety Net (VSN) is a global network of websites aimed at helping people judge the quality of online information on vaccine safety. It was established in 2003 by the World Health Organization (WHO), which had previously set up the independent Global Advisory Committee on Vaccine Safety (GACVS), prompted by concern from public health officials regarding the dissemination of potentially harmful health information via the web. By appraising websites, using credibility and content criteria defined by GACVS, the VSN has been developed to deliver information that is easy to access and up-to-date. As of 2020, the initiative has 89 member sites in 40 countries and 35 languages.

The International Center for Ethnobotanical Education, Research, and Service (ICEERS) is a non-profit organization (NPO), headquartered in Barcelona. ICEERS is dedicated to transforming society's relationship with psychoactive plants by engaging with some of the fundamental issues resulting from the globalization of ayahuasca, iboga, and other ethnobotanicals. Founded in 2009, ICEERS is registered as a non-profit organization, and has charitable status in the Netherlands and Spain, and through partner organizations in the US and UK. ICEERS also has consultative status with the United Nations’ ECOSOC.

References

  1. "EVI and Brighton Collaboration Foundation (BCF) sign Memorandum of Understanding (MoU)". Archived from the original on 2011-10-31. Retrieved 2012-07-17.
  2. Kohl, Katrin S.; Bonhoeffer, Jan; Braun, M. Miles; Chen, Robert T.; Duclos, Philippe; Heijbel, Harald; Heininger, Ulrich; Loupi, Elisabeth; Marcy, S. Michael (February 2005), Henriksen, Kerm; Battles, James B.; Marks, Eric S.; Lewin, David I. (eds.), "The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization", Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology), Advances in Patient Safety, Rockville (MD): Agency for Healthcare Research and Quality (US), PMID   21249832, archived from the original on 2022-12-12, retrieved 2023-07-04
  3. Chen RT (1999). "Vaccine risks: real, perceived and unknown". Vaccine. 17 (Suppl 3): S41-6. doi:10.1016/s0264-410x(99)00292-3. PMID   10559533.
  4. 1 2 "Our Partners". Brighton Collaboration. Archived from the original on 2023-07-04. Retrieved 2023-07-04.